Farxiga (far-SEE-guh) for type 2 diabetes will soon hit shelves
March 2014
Farxiga (far-SEE-guh) for type 2 diabetes will soon hit shelves.
Think of Farxiga (dapagliflozin) as similar to Invokana (canagliflozin). They increase glucose excretion in the urine by inhibiting sodium-glucose co-transporter 2 (SGLT2) in the kidney.
Both lower A1C by about 1%...decrease weight by about 4 to 7 pounds...modestly lower BP...and slightly increase LDL cholesterol.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote